NZ596916A - Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate - Google Patents

Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate

Info

Publication number
NZ596916A
NZ596916A NZ596916A NZ59691610A NZ596916A NZ 596916 A NZ596916 A NZ 596916A NZ 596916 A NZ596916 A NZ 596916A NZ 59691610 A NZ59691610 A NZ 59691610A NZ 596916 A NZ596916 A NZ 596916A
Authority
NZ
New Zealand
Prior art keywords
treatment
restoration
portal hypertension
liver function
ornithine phenylacetate
Prior art date
Application number
NZ596916A
Other languages
English (en)
Inventor
Keith Anderson
Rajiv Jalan
Original Assignee
Ucl Business Plc
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc, Ocera Therapeutics Inc filed Critical Ucl Business Plc
Priority to NZ61509110A priority Critical patent/NZ615091A/en
Publication of NZ596916A publication Critical patent/NZ596916A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NZ596916A 2009-06-08 2010-06-08 Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate NZ596916A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ61509110A NZ615091A (en) 2009-06-08 2010-06-08 Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18515809P 2009-06-08 2009-06-08
US24074809P 2009-09-09 2009-09-09
US29637710P 2010-01-19 2010-01-19
PCT/US2010/037838 WO2010144498A2 (en) 2009-06-08 2010-06-08 Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate

Publications (1)

Publication Number Publication Date
NZ596916A true NZ596916A (en) 2013-09-27

Family

ID=43309444

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ596916A NZ596916A (en) 2009-06-08 2010-06-08 Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
NZ61509110A NZ615091A (en) 2009-06-08 2010-06-08 Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ61509110A NZ615091A (en) 2009-06-08 2010-06-08 Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate

Country Status (18)

Country Link
US (2) US20120157526A1 (cg-RX-API-DMAC7.html)
EP (3) EP2440200B8 (cg-RX-API-DMAC7.html)
JP (3) JP5749255B2 (cg-RX-API-DMAC7.html)
KR (2) KR101715008B1 (cg-RX-API-DMAC7.html)
CN (2) CN102625699B (cg-RX-API-DMAC7.html)
AU (1) AU2010258888B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1012956A8 (cg-RX-API-DMAC7.html)
CA (2) CA2997484C (cg-RX-API-DMAC7.html)
DK (2) DK2440200T3 (cg-RX-API-DMAC7.html)
EA (2) EA025735B1 (cg-RX-API-DMAC7.html)
ES (2) ES2517340T3 (cg-RX-API-DMAC7.html)
IL (2) IL216811A (cg-RX-API-DMAC7.html)
MX (3) MX375116B (cg-RX-API-DMAC7.html)
NZ (2) NZ596916A (cg-RX-API-DMAC7.html)
PL (1) PL2440200T3 (cg-RX-API-DMAC7.html)
SG (1) SG176675A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010144498A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201108988B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2153870E (pt) 2004-11-26 2014-03-12 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
NZ708458A (en) 2009-04-03 2017-02-24 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
EA025735B1 (ru) 2009-06-08 2017-01-30 ЮСиЭл БИЗНЕС ПиЭлСи Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата
ES2720148T3 (es) 2010-10-06 2019-07-18 Ocera Therapeutics Inc Métodos de fabricación de fenilacetato de L-ornitina
CN102993037B (zh) * 2012-11-20 2015-03-04 南京工业大学 一种l-鸟氨酸苯乙酸盐的制备方法
RS58375B1 (sr) 2014-01-29 2019-03-29 Umecrine Cognition Ab Steroidno jedinjenje za upotrebu u lečenju hepatične encefalopatije
CA2965325A1 (en) 2014-10-24 2016-04-28 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
NZ732632A (en) * 2014-11-24 2021-07-30 Ucl Business Ltd Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
EP3285756B1 (en) * 2015-04-20 2023-02-22 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
JP6989495B2 (ja) * 2015-09-25 2022-01-05 オセラ セラピューティクス， インコーポレイテッド Ｌ−オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる神経細胞喪失の治療および予防
US11219611B2 (en) * 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
CA3004331A1 (en) * 2015-11-13 2017-05-18 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
CN106109429A (zh) * 2016-07-26 2016-11-16 北京百奥药业有限责任公司 一种苯丁酸钠片剂及其制备方法
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11160826B1 (en) 2017-03-03 2021-11-02 United States Government As Represented By The Department Of Veterans Affairs Cholesterol lowering drugs for the treatment of hepatic encephalopathy
KR20200024145A (ko) 2017-05-11 2020-03-06 오세라 테라퓨틱스, 아이엔씨. L-오르니틴 페닐아세테이트의 제조방법
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
WO2019173148A1 (en) * 2018-03-05 2019-09-12 The United States Government As Represented By The United States Department Of Veterans Affairs Cholesterol lowering drugs for the treatment of hepatic encephalopathy
AR115585A1 (es) 2018-06-20 2021-02-03 Axcella Health Inc Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo
JP2022533569A (ja) 2019-05-09 2022-07-25 オセラ セラピューティクス， インコーポレイテッド 肝性脳症を評価および処置する方法
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
KR102237526B1 (ko) * 2019-11-07 2021-04-07 한국식품연구원 오르니틴 생성능이 우수한 락토바실러스 브레비스 wikim47를 이용한 마늘 발효 조성물
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (cg-RX-API-DMAC7.html) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
FR2113774A1 (en) 1970-11-13 1972-06-30 Roques Ets Prepn of l-ornithine salts with org acids - using silver oxides
US4100161A (en) 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4352814A (en) 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US4857555A (en) 1985-09-12 1989-08-15 Brigham & Women's Hospital Method of treating catabolic dysfunction
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5139981A (en) 1987-06-24 1992-08-18 Union Carbide Chemicals & Plastics Technology Corporation Process for preparing silver(I)-exchanged resins
JP2522034B2 (ja) 1988-12-27 1996-08-07 味の素株式会社 α−ケト酸・アミノ酸塩化合物及びその製造方法
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
DE4020980C1 (cg-RX-API-DMAC7.html) 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US5856481A (en) 1994-07-28 1999-01-05 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
IL139728A (en) 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
FI972744L (fi) * 1995-02-23 1997-08-22 Novartis Nutrition Ag Aminohappokokoonpanoja ja niiden käyttö kliinisessä ravinnossa
AU2251897A (en) 1996-02-13 1997-09-02 Trustees Of The University Of Pennsylvania, The Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
EP1179347A4 (en) 1999-05-21 2002-06-26 Takeda Chemical Industries Ltd CONTROL SUBSTANCES FOR LIVER FUNCTION
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
CN1304723A (zh) 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物
DE60233558D1 (de) 2001-03-15 2009-10-15 Takashi Abe Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
AU2003261825A1 (en) 2002-08-30 2004-03-19 Ajinomoto Co., Inc. Therapeutic agent for hepatic disease
US20050059150A1 (en) 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
KR20110124317A (ko) 2004-05-06 2011-11-16 오스테올로지스 에이에스 금속 유기 염의 제조를 위한 고 수율 및 고속 합성 방법
WO2006059237A1 (en) 2004-08-30 2006-06-08 Lunamed, Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
PT2153870E (pt) * 2004-11-26 2014-03-12 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
WO2007077995A1 (ja) 2006-01-05 2007-07-12 Kyowa Hakko Kogyo Co., Ltd. 筋肉増量剤
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
CA2727088A1 (en) 2008-06-04 2009-12-10 Phenolics, Llc Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
NZ708458A (en) 2009-04-03 2017-02-24 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
CA2763894A1 (en) 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Use of rifaximin to maintain remission of hepatic encephalopathy
EA025735B1 (ru) 2009-06-08 2017-01-30 ЮСиЭл БИЗНЕС ПиЭлСи Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
JP2011236160A (ja) 2010-05-11 2011-11-24 Shinshu Univ 非アルコール性肝疾患治療薬
ES2720148T3 (es) 2010-10-06 2019-07-18 Ocera Therapeutics Inc Métodos de fabricación de fenilacetato de L-ornitina
ES2654774T3 (es) 2012-11-21 2018-02-15 Horizon Therapeutics, Llc Métodos para administrar y evaluar fármacos de recuperación de nitrógeno para el tratamiento de encefalopatía hepática
CN103705490B (zh) 2013-10-31 2016-08-17 蚌埠丰原医药科技发展有限公司 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺
NZ732632A (en) 2014-11-24 2021-07-30 Ucl Business Ltd Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
EP3285756B1 (en) 2015-04-20 2023-02-22 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
JP6989495B2 (ja) 2015-09-25 2022-01-05 オセラ セラピューティクス， インコーポレイテッド Ｌ−オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる神経細胞喪失の治療および予防
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate

Also Published As

Publication number Publication date
WO2010144498A2 (en) 2010-12-16
IL248696B (en) 2020-05-31
ES2517340T3 (es) 2014-11-03
JP6250588B2 (ja) 2017-12-20
MX2020009703A (es) 2020-10-07
KR101715008B1 (ko) 2017-03-22
WO2010144498A9 (en) 2011-04-28
NZ615091A (en) 2015-03-27
CA2764587A1 (en) 2010-12-16
JP5749255B2 (ja) 2015-07-15
IL216811A0 (en) 2012-02-29
CA2997484C (en) 2020-05-12
US20180161293A1 (en) 2018-06-14
CN102625699A (zh) 2012-08-01
EP2440200A2 (en) 2012-04-18
SG176675A1 (en) 2012-01-30
CA2997484A1 (en) 2010-12-16
BRPI1012956A2 (pt) 2017-06-06
ZA201108988B (en) 2015-04-29
AU2010258888A1 (en) 2012-02-02
ES2728948T3 (es) 2019-10-29
EP2440200A4 (en) 2012-11-28
DK2440200T3 (en) 2014-12-08
JP2017066153A (ja) 2017-04-06
HK1203419A1 (en) 2015-10-30
KR20170026672A (ko) 2017-03-08
EA201171396A1 (ru) 2012-10-30
EP2440200B8 (en) 2014-10-15
US11266620B2 (en) 2022-03-08
EP2799067B1 (en) 2019-04-03
IL248696A0 (en) 2016-12-29
BRPI1012956A8 (pt) 2021-11-03
JP2015163635A (ja) 2015-09-10
CN104434894A (zh) 2015-03-25
HK1174264A1 (en) 2013-06-07
PL2440200T3 (pl) 2015-08-31
JP6527497B2 (ja) 2019-06-05
US20120157526A1 (en) 2012-06-21
CA2764587C (en) 2018-04-24
EP3517110A1 (en) 2019-07-31
KR20120047891A (ko) 2012-05-14
DK2799067T3 (da) 2019-06-03
MX375116B (es) 2025-03-06
IL216811A (en) 2016-11-30
EP2440200B1 (en) 2014-08-27
EA025735B1 (ru) 2017-01-30
AU2010258888B2 (en) 2014-08-07
CN102625699B (zh) 2014-08-20
JP2012529523A (ja) 2012-11-22
EA201691430A1 (ru) 2017-02-28
EP2799067A1 (en) 2014-11-05
MX2011013129A (es) 2012-03-14

Similar Documents

Publication Publication Date Title
NZ596916A (en) Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
CA140586S (en) Dental cleaning instrument
PH12012502016A1 (en) Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
MY148495A (en) Oral compositions for treating tooth sensitivity and methods of use and manufacture thereof
MX342951B (es) Composiciones terapeuticamente activas y su metodo de uso.
AU324656S (en) Pacifier
MX2012007933A (es) Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.
WO2009079451A3 (en) Compositions and methods of promoting wound healing
AU337044S (en) Oral care implement
AU2014250643B2 (en) Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
AU324657S (en) Pacifier
AU337319S (en) Oral care implement
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
AU337592S (en) Oral care implement
MX2010012106A (es) Analogos de 1-metilnicotinamida.
MX2010013790A (es) Composiciones y metodos para tratar inflamacion de corneas.
MX2008011312A (es) Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos.
PH12012501273A1 (en) Oral care compositions and methods
UA27829U (en) Method for treating prosthetic stomatitis against the background of metabolic syndrome
UA27830U (en) Method for treating prosthetic stomatitis against the background of metabolic syndrome
UA64530U (ru) Способ лечения гиперестезии твердых тканей зубов у пациентов c гастроезофагеальной рефлюксной болезнью
UA36750U (ru) Способ лечения лейкоплакии слизистой оболочки полости рта
TW200738229A (en) Memantine for the normalization of visual acuity deficits
UA27828U (en) Method for treating prosthetic stomatitis against the background metabolic syndrome
UA27141U (en) Method for manufacturing base of denture

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: OCERA THERAPEUTICS, INC., US

Free format text: OLD OWNER(S): UCL BUSINESS PLC; OCERA THERAPEUTICS, INC.; RAJIV JALAN; KEITH ANDERSON

Owner name: UCL BUSINESS PLC, GB

Free format text: OLD OWNER(S): UCL BUSINESS PLC; OCERA THERAPEUTICS, INC.; RAJIV JALAN; KEITH ANDERSON

S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CORRECTION TO TITLE (54)

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 JUN 2017 BY CPA GLOBAL

Effective date: 20140424

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2018 BY CPA GLOBAL

Effective date: 20170428

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2019 BY CPA GLOBAL

Effective date: 20180426

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2020 BY CPA GLOBAL

Effective date: 20190425

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2021 BY COMPUTER PACKAGES INC

Effective date: 20200519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2022 BY COMPUTER PACKAGES INC

Effective date: 20210517

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2023 BY COMPUTER PACKAGES INC

Effective date: 20220519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2024 BY COMPUTER PACKAGES INC

Effective date: 20230518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2025 BY COMPUTER PACKAGES INC

Effective date: 20240917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250724